Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 21;10(4):255-258.
doi: 10.4103/tjo.tjo_63_20. eCollection 2020 Oct-Dec.

Intraocular pressure reduction in glaucoma: Does every mmHg count?

Hari Jayaram  1   2   3
Affiliations
Review

Intraocular pressure reduction in glaucoma: Does every mmHg count?

Hari Jayaram. Taiwan J Ophthalmol. .

Abstract

The reduction of intraocular pressure is currently the only known modifiable risk factor for the treatment of Glaucoma, which is the leading cause of irreversible worldwide blindness. This concise review discusses the evidence underpinning the reduction of intraocular pressure in the treatment of glaucoma, the role of target intraocular pressure in clinical practice and appraises clinical data supporting the concept that every mmHg of intraocular pressure reduction is important in reducing the risk of developing glaucoma and the progression of existing disease. Every mmHg in IOP reduction is important, with evidence showing an impact on both functional and structural progression but does not however explain all glaucoma risk.

Keywords: Glaucoma; Intraocular Pressure; Rate of Progression.

PubMed Disclaimer

Conflict of interest statement

The author declares that there are no conflicts of interest of this paper.

Figures

Figure 1
Figure 1
Risk of lifetime visual impairment – the relationship between age at diagnosis and rate of progression. (Adapted from the European Glaucoma Society Guidelines[10])
Figure 2
Figure 2
Risk of lifetime visual impairment – the relationship between the rate of progression and time of intervention. (Adapted from Caprioli and Zeyen[15])
See this image and copyright information in PMC

References

    1. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014;121:2081–90. - PubMed
    1. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–8. - PubMed
    1. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997;38:83–91. - PubMed
    1. Rahman F, Zekite A, Bunce C, Jayaram H, Flanagan D. Recent trends in vision impairment certifications in England and Wales. Eye (Lond) 2020;34:1271–8. - PMC - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13. - PubMed